Japanese Correspondence
Yamada Science Foundation
YSF TOPOverview of YSFSupport for ScienceYamada Conference : YCYamada Symposium : YSResearch and YC YS ReportsPastsupport

Progress Report of YSF Supported Science Program


Summary of Research Projects (Supports in 2003 Fiscal Year)
returns to the listreturns to the list
Subjects Functional Analysis of Receptor-Type Protein Tyrosine Phosphatase ζ
Representative researcher National Institute for Basic Biology Masaharu NODA
Protein tyrosine phosphorylation plays crucial roles in various biological aspects. However, physiological functions of individual PTPs are poorly understood due to a lack of information concerning substrates of respective PTPs. Protein tyrosine phosphatase ζ (PTPζ/RPTPβ/Ptprz) is a receptor-type PTP predominantly expressed in the brain as a chondroitin sulfate proteoglycan. We previously revealed that PTPζ binds pleiotrophin and midkine, closely related heparin-binding growth factors. We now developed a genetic method "yeast substrate-trapping system" to isolate substrates for PTPs, and successfully identified substrate molecules for PTPζ including Git1 and p190 RhoGAP, together with many interacting molecules. RPTPs transduce the extracellular signals through the change of their PTP activity, however, our knowledge about the regulatory mechanism is still limited. We demonstrated that oligomers of pleiotrophin dose-dependently enhance the tyrosine phosphorylation of Git1. PTPζ thus appears to be constitutively active in the monomeric form and negatively regulated by dimerization. Furthermore, we found that mutant mice deficient in PTPζ exhibited enhanced long-term potentiation (LTP) in the CA1 region of hippocampal slices and impaired spatial learning abilities in an age-dependent manner. The enhanced LTP was canceled out by pharmacological inhibition of Rho-associated kinase (ROCK), a major downstream effector of Rho. These findings suggest that the lack of PTPζ leads to aberrant activation of ROCK and resultantly to the enhanced LTP and learning impairments.